Novartis India Limited (NOVARTIND.BO)
INR 789.4
(0.41%)
INR 789.4
(0.41%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 851.9 Million INR | -17.58% |
| 2022 | 1.03 Billion INR | 2878.49% |
| 2021 | -37.2 Million INR | -117.8% |
| 2020 | 209 Million INR | 107.34% |
| 2019 | 100.8 Million INR | -80.53% |
| 2018 | 517.7 Million INR | -33.93% |
| 2017 | 783.6 Million INR | 36.95% |
| 2016 | 572.2 Million INR | -71.14% |
| 2015 | 1.98 Billion INR | 150.65% |
| 2014 | 791.1 Million INR | -19.71% |
| 2013 | 985.3 Million INR | -17.71% |
| 2012 | 1.19 Billion INR | -21.24% |
| 2011 | 1.52 Billion INR | 3.65% |
| 2010 | 1.46 Billion INR | 26.45% |
| 2009 | 1.15 Billion INR | 11.84% |
| 2008 | 1.03 Billion INR | 6.66% |
| 2007 | 972.34 Million INR | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | 257.39 Million INR | 75.34% |
| 2024 Q2 | 204 Million INR | -20.75% |
| 2023 Q4 | 146.8 Million INR | -44.75% |
| 2023 FY | 851.9 Million INR | -17.58% |
| 2023 Q2 | 236.8 Million INR | 16.88% |
| 2023 Q3 | 265.7 Million INR | 12.2% |
| 2023 Q1 | 202.6 Million INR | -19.02% |
| 2022 Q2 | 183.5 Million INR | -64.97% |
| 2022 Q3 | 76.1 Million INR | -58.53% |
| 2022 FY | 1.03 Billion INR | 2878.49% |
| 2022 Q4 | 250.2 Million INR | 228.78% |
| 2022 Q1 | 523.8 Million INR | 324.13% |
| 2021 Q4 | -233.7 Million INR | -468.03% |
| 2021 FY | -37.2 Million INR | -117.8% |
| 2021 Q1 | 62.8 Million INR | -35.26% |
| 2021 Q2 | 70.2 Million INR | 11.78% |
| 2021 Q3 | 63.5 Million INR | -9.54% |
| 2020 FY | 209 Million INR | 107.34% |
| 2020 Q3 | -7.1 Million INR | -109.44% |
| 2020 Q1 | 43.9 Million INR | -35.25% |
| 2020 Q4 | 97 Million INR | 1466.2% |
| 2020 Q2 | 75.2 Million INR | 71.3% |
| 2019 Q1 | 7.9 Million INR | -95.95% |
| 2019 Q4 | 67.8 Million INR | -12.29% |
| 2019 FY | 100.8 Million INR | -80.53% |
| 2019 Q2 | -52.2 Million INR | -760.76% |
| 2019 Q3 | 77.3 Million INR | 248.08% |
| 2018 FY | 517.7 Million INR | -33.93% |
| 2018 Q4 | 195.3 Million INR | 51.75% |
| 2018 Q3 | 128.7 Million INR | 37.35% |
| 2018 Q2 | 93.7 Million INR | -6.3% |
| 2018 Q1 | 100 Million INR | -62.22% |
| 2017 Q1 | 70.3 Million INR | 141.58% |
| 2017 FY | 783.6 Million INR | 36.95% |
| 2017 Q3 | 187.4 Million INR | -28.25% |
| 2017 Q2 | 261.2 Million INR | 271.55% |
| 2017 Q4 | 264.7 Million INR | 41.25% |
| 2016 Q1 | 190.7 Million INR | -11.43% |
| 2016 Q2 | 222.1 Million INR | 16.47% |
| 2016 FY | 572.2 Million INR | -71.14% |
| 2016 Q4 | 29.1 Million INR | -77.67% |
| 2016 Q3 | 130.3 Million INR | -41.33% |
| 2015 FY | 1.98 Billion INR | 150.65% |
| 2015 Q4 | 215.3 Million INR | -63.15% |
| 2015 Q3 | 584.3 Million INR | -43.65% |
| 2015 Q2 | 1.03 Billion INR | 677.29% |
| 2015 Q1 | 133.4 Million INR | -74.32% |
| 2014 FY | 791.1 Million INR | -19.71% |
| 2014 Q1 | 143.1 Million INR | -40.08% |
| 2014 Q2 | 140.4 Million INR | -1.89% |
| 2014 Q3 | -11.8 Million INR | -108.4% |
| 2014 Q4 | 519.4 Million INR | 4501.69% |
| 2013 Q4 | 238.8 Million INR | 56.8% |
| 2013 FY | 985.3 Million INR | -17.71% |
| 2013 Q3 | 152.3 Million INR | -66.56% |
| 2013 Q2 | 455.5 Million INR | 228.41% |
| 2013 Q1 | 138.7 Million INR | -43.18% |
| 2012 Q4 | 244.1 Million INR | -15.83% |
| 2012 FY | 1.19 Billion INR | -21.24% |
| 2012 Q1 | 269.8 Million INR | -18.04% |
| 2012 Q2 | 393.4 Million INR | 45.81% |
| 2012 Q3 | 290 Million INR | -26.28% |
| 2011 FY | 1.52 Billion INR | 3.65% |
| 2011 Q2 | 431.8 Million INR | 0.0% |
| 2011 Q3 | 383.5 Million INR | -11.19% |
| 2011 Q4 | 329.2 Million INR | -14.16% |
| 2010 FY | 1.46 Billion INR | 26.45% |
| 2009 FY | 1.15 Billion INR | 11.84% |
| 2008 FY | 1.03 Billion INR | 6.66% |
| 2007 FY | 972.34 Million INR | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 6.15 Billion INR | 86.166% |
| Aurobindo Pharma Limited | 31.72 Billion INR | 97.315% |
| Glenmark Life Sciences Limited | 4.7 Billion INR | 81.909% |
| Granules India Limited | 4.05 Billion INR | 78.982% |
| Indoco Remedies Limited | 984.6 Million INR | 13.478% |
| Achyut Healthcare Limited | 5.73 Million INR | -14762.177% |
| Ajanta Pharma Limited | 8.16 Billion INR | 89.562% |
| Alkem Laboratories Limited | 17.95 Billion INR | 95.256% |
| Alpa Laboratories Limited | 167.76 Million INR | -407.794% |
| Brooks Laboratories Limited | -195.91 Million INR | 534.823% |
| AstraZeneca Pharma India Limited | 1.61 Billion INR | 47.254% |
| Bajaj HealthCare Limited | -837.93 Million INR | 201.667% |
| Bliss GVS Pharma Limited | 754.54 Million INR | -12.903% |
| Dr. Reddy's Laboratories Limited | 55.68 Billion INR | 98.47% |
| Eris Lifesciences Limited | 3.91 Billion INR | 78.267% |
| FDC Limited | 3.05 Billion INR | 72.089% |
| Glenmark Pharmaceuticals Limited | -15.01 Billion INR | 105.673% |
| Gufic Biosciences Limited | 861.35 Million INR | 1.098% |
| Ind-Swift Laboratories Limited | 4.2 Billion INR | 79.763% |
| Ipca Laboratories Limited | 5.47 Billion INR | 84.436% |
| Jagsonpal Pharmaceuticals Limited | 224.63 Million INR | -279.246% |
| Krebs Biochemicals & Industries Limited | -197.28 Million INR | 531.814% |
| Lasa Supergenerics Limited | -217.3 Million INR | 492.028% |
| Laurus Labs Limited | 1.6 Billion INR | 46.939% |
| Lupin Limited | 19.14 Billion INR | 95.55% |
| Mankind Pharma Limited | 19.12 Billion INR | 95.547% |
| Medicamen Biotech Limited | 109.31 Million INR | -679.343% |
| Medico Remedies Limited | 82.9 Million INR | -927.512% |
| Megasoft Limited | -127.46 Million INR | 768.335% |
| NATCO Pharma Limited | 13.88 Billion INR | 93.864% |
| Piramal Pharma Limited | 178.2 Million INR | -378.058% |
| RPG Life Sciences Limited | 876.6 Million INR | 2.818% |
| Sigachi Industries Limited | 571.8 Million INR | -48.985% |
| Sun Pharmaceutical Industries Limited | 95.76 Billion INR | 99.11% |
| Suven Pharmaceuticals Limited | 3 Billion INR | 71.63% |
| Syncom Formulations (India) Limited | 253.14 Million INR | -236.53% |
| Unichem Laboratories Limited | -704.74 Million INR | 220.881% |
| Wanbury Limited | 559.56 Million INR | -52.244% |
| Windlas Biotech Limited | 581.87 Million INR | -46.407% |
| ZIM Laboratories Limited | 172.46 Million INR | -393.958% |
| Zydus Lifesciences Limited | 38.59 Billion INR | 97.793% |
| Sun Pharma Advanced Research Company Limited | -3.87 Billion INR | 122.001% |
| Divi's Laboratories Limited | 16 Billion INR | 94.676% |
| Hester Biosciences Limited | 188.89 Million INR | -351.003% |
| Procter & Gamble Health Limited | 2 Billion INR | 57.613% |
| Amrutanjan Health Care Limited | 449.72 Million INR | -89.426% |
| Bal Pharma Limited | 73.92 Million INR | -1052.431% |
| Strides Pharma Science Limited | -706.14 Million INR | 220.642% |
| Venus Remedies Limited | 284.9 Million INR | -199.009% |
| Aarti Pharmalabs Limited | 2.16 Billion INR | 60.724% |
| Nectar Lifesciences Limited | 49.95 Million INR | -1605.506% |
| Shilpa Medicare Limited | 318.74 Million INR | -167.269% |
| Aarti Drugs Limited | 1.71 Billion INR | 50.303% |
| IOL Chemicals and Pharmaceuticals Limited | 1.34 Billion INR | 36.629% |
| Suven Life Sciences Limited | -1.05 Billion INR | 181.074% |
| Ind-Swift Limited | 142.31 Million INR | -498.61% |
| Valiant Laboratories Limited | 3.19 Million INR | -26555.194% |
| J. B. Chemicals & Pharmaceuticals Limited | 5.52 Billion INR | 84.585% |
| Solara Active Pharma Sciences Limited | -5.67 Billion INR | 115.014% |
| Themis Medicare Limited | 435.23 Million INR | -95.732% |
| Hikal Limited | 696.02 Million INR | -22.396% |
| Torrent Pharmaceuticals Limited | 16.56 Billion INR | 94.857% |
| Sequent Scientific Limited | -358.69 Million INR | 337.503% |
| Wockhardt Limited | -4.63 Billion INR | 118.4% |
| Jubilant Pharmova Limited | 771 Million INR | -10.493% |
| Biofil Chemicals and Pharmaceuticals Limited | 7.09 Million INR | -11912.126% |
| Neuland Laboratories Limited | 3 Billion INR | 71.611% |
| Morepen Laboratories Limited | 961.59 Million INR | 11.408% |
| Kilitch Drugs (India) Limited | 146.01 Million INR | -483.437% |
| Mangalam Drugs & Organics Limited | -90.71 Million INR | 1039.074% |